FSD Pharma fully funded to continue progress on its Phase 2 FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) CEO Raza Bokhari tells Proactive the biopharma group is fully funded to continue progress on its Phase 2 study to treat hospitalized coronavirus patients. Bokhari says its most recent fundraising gives the firm $9.5M to conduct the trial, which will begin dosing patients in the next couple of weeks. Despite a recent decline in share price, Bokhari says the group is in execution mode, and has delivered more milestones ahead of schedule.https://youtu.be/DK7npksg7zo